Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 1Phase 1 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 1CNS 1

Conditions

Squamous Intraepithelial Lesions 1Prolactinoma 1Precancerous Conditions 1Pituitary Neoplasms 1Growth Hormone-Secreting Pituitary Adenoma 1Gliosarcoma 1Glioblastoma 1Central Nervous System Neoplasms 1Anus Neoplasms 1Adenoma, Chromophobe 1Adenoma, Basophil 1Adenoma, Acidophil 1

Interventions

Radiotherapy 54Temozolomide 50Filgrastim 25Cyclophosphamide 25Etoposide 24Cisplatin 22Carboplatin 22Vincristine 19Chemotherapy, Adjuvant 18Peripheral Blood Stem Cell Transplantation 15Thiotepa 13Carmustine 12Thalidomide 10Methotrexate 9Magnetic Resonance Spectroscopy 9Irinotecan 9Bevacizumab 9Granulocyte Colony-Stimulating Factor 7sargramostim 6Topotecan 6Lomustine 6X-Rays 5Tamoxifen 5Specimen Handling 5Phantoms, Imaging 5O(6)-benzylguanine 5Ifosfamide 5Erlotinib Hydrochloride 5Drug Therapy 5Celecoxib 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Central Nervous System Neoplasms × DNA Methylation × Clear all
NCT00601289 2020-07-31

Temozolomide in Treating Patients With Invasive Pituitary Tumors

Jonsson Comprehensive Cancer Center

Phase 2 Withdrawn
CNSEndocrine

Adenoma, Basophil, Adenoma, Chromophobe, Adenoma, Acidophil, Pituitary Neoplasms, Prolactinoma, Central Nervous System Neoplasms, Growth Hormone-Secreting Pituitary Adenoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡